400 0 1 Cash used in operations, Gene Therapy Manufacturing Facility (GTMF) Capital Expenses and select non-recurring uses of cash 2 2021: ~$55M GTMF; 2022: ~$90M GTMF, $75M GeneTx Acquisition, $30M Evkeeza License; 2023: ~$20M GTMF 3 Estimated cash, cash equivalents, and available-for-sale investments as of December 31, 2022 (unaudited) 9 Confidential and Proprietary Abnormal bone metabolism leads to increased bone resorption, inadequate bone production | --- | --- | --- | --- | --- | --- | --- | |-------- ...

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2022 Earnings Conference Call November 2, 2022 5:00 PM ET Company Participants Joshua Higa - Head of Investor Relations Emil Kakkis - Founder, President and Chief Executive Officer Erik Harris - Executive Vice President and Chief Commercial Officer Mardi Dier - Executive Vice President and Chief Financial Officer Camille Bedrosian - Executive Vice President and Chief Medical Officer Conference Call Participants Gena Wang - Barclays Joori Park - SVB Securities ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File No. 001-36276 ULTRAGENYX PHARMACEUTICAL INC. (Exact name of registrant as specified in its charter) (Former Name, Former Address and ...

Corporate Deck July 2022 Legal Warning Cautionary note regarding forward-looking statements: This presentation contains forward-looking statements, including, but not limited to, statements regarding our expectations and projections regarding our future operating results and financial performance, anticipated cost or expense reductions, plans with respect to commercializing our product and product candidates, our translational research program, expectations regarding our manufacturing capabilities, the expe ...

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2022 Earnings Conference Call July 28, 2022 5:00 PM ET Company Participants Joshua Higa - Executive Director & Head, Investor Relations Emil Kakkis - Chief Executive Officer & President Erik Harris - Chief Commercial Officer Mardi Dier - Chief Financial Officer Camille Bedrosian - Chief Medical Officer Conference Call Participants Gena Wang - Barclays Joel Beatty - Baird Dae Gon Ha - Stifel Tazeen Ahmad - Bank of America Cory Kasimov - JPMorgan Yaron Werber - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File No. 001-36276 ULTRAGENYX PHARMACEUTICAL INC. (Exact name of registrant as specified in its charter) Delaware 27-2546083 (State or other ju ...

Corporate Deck May 2022 Legal Warning Cautionary note regarding forward-looking statements: This presentation contains forward-looking statements, including, but not limited to, statements regarding our expectations and projections regarding our future operating results and financial performance, anticipated cost or expense reductions, plans with respect to commercializing our product and product candidates, our translational research program, expectations regarding our manufacturing capabilities, the expec ...

Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Joshua Higa - Director, IR & Corporate Communications Emil Kakkis - President, CEO & Director Erik Harris - EVP & Chief Commercial Officer Mardi Dier - EVP & CFO Camille Bedrosian - Chief Medical Officer & EVP Conference Call Participants Huidong Wang - Barclays Bank Yigal Nochomovitz - Citigroup Tazeen Ahmad - Bank of America Merrill Lynch Joel Beatty - Robert W. Baird & Co. Maurice Ra ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) For the transition period from to . Commission File No. 001-36276 ULTRAGENYX PHARMACEUTICAL INC. (Exact name of registrant as specified in its charter) Delaware 27-2546083 (State or other j ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36276 Ultragenyx Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 27-2546083 (State or other jurisdiction of inc ...